Gadolinium and nephrogenic systemic fibrosis: Time to tighten practice

Pediatric Radiology

Volumn 38, Issue 5, 2008, Pages 489-496

  Mendichovszky, Iosif A ^a   Marks, Stephen D ^b   Simcock, Clare M ^c   Olsen, Øystein E ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

Children; Chronic kidney disease; Gadolinium; Nephrogenic systemic fibrosis

Indexed keywords

GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE;

COMPUTER ASSISTED TOMOGRAPHY; HEMODIALYSIS; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MEDICAL PRACTICE; NEPHROGENIC FIBROSING DERMOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM DTPA; HUMANS; PEDIATRICS; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SKIN DISEASES;

EID: 41849136088     PISSN: 03010449     EISSN: 14321998     Source Type: Journal    
DOI: 10.1007/s00247-007-0633-8     Document Type: Review

References (54)

1. Cowper SE, Robin HS, Steinberg SM et al (2000) Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356:1000-1001
2. Ting WW, Stone MS, Madison KC et al (2003) Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 139:903-906
3. Jimenez SA, Artlett CM, Sandorfi N et al (2004) Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 50:2660-2666
4. Kucher C, Steere J, Elenitsas R et al (2006) Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 54:S31-S34
5. Cowper SE (2001-2007) Nephrogenic Fibrosing Dermopathy (NFD/NSF Website). http://www.icnfdr.org/. Cited 20 September 2007
6. Cowper SE (2003) Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 15:785-790
7. Mackay-Wiggan JM, Cohen DJ, Hardy MA et al (2003) Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 48:55-60
8. Swartz RD, Crofford LJ, Phan SH et al (2003) Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 114:563-572
9. Cowper SE (2005) Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 46:763-765
10. Gibson SE, Farver CF, Prayson RA (2006) Multiorgan involvement in nephrogenic fibrosing dermopathy: an autopsy case and review of the literature. Arch Pathol Lab Med 130:209-212
11. Neudecker BA, Stern R, Mark LA et al (2005) Scleromyxedema-like lesions of patients in renal failure contain hyaluronan: a possible pathophysiological mechanism. J Cutan Pathol 32:612-615
12. Solomon GJ, Wu E, Rosen PP (2007) Nephrogenic systemic fibrosis mimicking inflammatory breast carcinoma. Arch Pathol Lab Med 131:145-148
13. Obermoser G, Emberger M, Wieser M et al (2004) Nephrogenic fibrosing dermopathy in two patients with systemic lupus erythematosus. Lupus 13:609-612
14. Maloo M, Abt P, Kashyap R et al (2006) Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 6:2212-2217
15. Cowper SE, Bucala R (2003) Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol 25:358
16. Quan TE, Cowper SE, Bucala R (2006) The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 8:145-150
17. Lauchli S, Zortea-Caflisch C, Nestle FO et al (2004) Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis. Dermatology 208:278-280
18. Gilliet M, Cozzio A, Burg G et al (2005) Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 152:531-536
19. Baron PW, Cantos K, Hillebrand DJ et al (2003) Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 25:204-209
20. Kafi R, Fisher GJ, Quan T et al (2004) UV-A1 phototherapy improves nephrogenic fibrosing dermopathy. Arch Dermatol 140:1322-1324
21. Chung HJ, Chung KY (2004) Nephrogenic fibrosing dermopathy: response to high-dose intravenous immunoglobulin. Br J Dermatol 150:596-597
22. Grobner T (2006) Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21:1104-1108
23. Marckmann P, Skov L, Rossen K et al (2006) Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359-2362
24. High WA, Ayers RA, Chandler J et al (2007) Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56:21-26
25. Boyd AS, Zic JA, Abraham JL (2007) Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56:27-30
26. Sadowski EA, Bennett LK, Chan MR et al (2007) Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 243:148-157
27. Khurana A, Runge VM, Narayanan M et al (2007) Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 42:139-145
28. Broome DR, Girguis MS, Baron PW et al (2007) Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR 188:586-592
29. Kuo PH, Kanal E, Abu-Alfa AK et al (2007) Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 242:647-649
30. GE Healthcare (2007) Omniscan safety update. http://www.amershamhealth- us.com/omniscan/. Cited 20 September 2007
31. Bayer Healthcare Pharmaceuticals (2007) Magnevist labeling update, May 23, 2007. http://www.imaging.bayerhealthcare.com/html/magnevist/labeling_update. html. Cited 20 September 2007
32. Leiner T, Herborn CU, Goyen M (2007) Nephrogenic systemic fibrosis is not exclusively associated with gadodiamide. Eur Radiol 17:1921-1923
33. Collidge TA, Thomson PC, Mark PB et al (2007)Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort.Radiology. DOI 2451070353
34. Marckmann P, Skov L, Rossen K et al (2007) Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant. DOI 10.1093/ndt/gfm261
35. Joffe P, Thomsen HS, Meusel M (1998) Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 5:491-502
36. Idee JM, Berthommier C, Goulas V et al (1998) Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation. Biometals 11:113-123
37. Corot C, Idee JM, Hentsch AM et al (1998) Structure-activity relationship of macrocyclic and linear gadolinium chelates: investigation of transmetallation effect on the zinc-dependent metallopeptidase angiotensin-converting enzyme. J Magn Reson Imaging 8:695-702
38. Behra-Miellet J, Gressier B, Brunet C et al (1996) Free gadolinium and gadodiamide, a gadolinium chelate used in magnetic resonance imaging: evaluation of their in vitro effects on human neutrophil viability. Methods Find Exp Clin Pharmacol 18:437-442
39. Green RW, Krestin GP (2006) Non-tissue specific extra cellular MR contrast media. In: Thomsen HS (ed) Contrast media: safety issues and ESUR guidelines. Springer, Berlin, pp 107-112
40. Idee JM, Port M, Raynal I et al (2006) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20:563-576
41. Harpur ES, Worah D, Hals PA et al (1993) Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 28 [Suppl 1]:S28-S43
42. Spencer AJ, Wilson SA, Batchelor J et al (1997) Gadolinium chloride toxicity in the rat. Toxicol Pathol 25:245-255
43. Mendoza FA, Artlett CM, Sandorfi N et al (2006) Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 35:238-249
44. Itoh N, Kawakita M (1984) Characterization of Gd3+ and Tb3+ binding sites on Ca2+,Mg2+-adenosine triphosphatase of sarcoplasmic reticulum. J Biochem (Tokyo) 95:661-669
45. Husztik E, Lazar G, Parducz A (1980) Electron microscopic study of Kupffer-cell phagocytosis blockade induced by gadolinium chloride. Br J Exp Pathol 61:624-630
46. Puttagunta NR, Gibby WA, Puttagunta VL (1996) Comparative transmetallation kinetics and thermodynamic stability of gadolinium-DTPA bis-glucosamide and other magnetic resonance imaging contrast media. Invest Radiol 31:619-624
47. Bartolini ME, Pekar J, Chettle DR et al (2003) An investigation of the toxicity of gadolinium based MRI contrast agents using neutron activation analysis. Magn Reson Imaging 21:541-544
48. Krasnow N (1977) Lanthanide binding to cardiac and skeletal muscle microsomes. Effects of adenosine triphosphate, cations, and ionophores. Arch Biochem Biophys 181:322-330
49. Lansman JB (1990) Blockade of current through single calcium channels by trivalent lanthanide cations. Effect of ionic radius on the rates of ion entry and exit. J Gen Physiol 95:679-696
50. Jan F, Segal JM, Dyer J et al (2003) Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 143:678-681
51. Jain SM, Wesson S, Hassanein A et al (2004) Nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 19:467-470
52. Dharnidharka VR, Wesson SK, Fennell RS (2007) Gadolinium and nephrogenic fibrosing dermopathy in pediatric patients. Pediatr Nephrol 22:1395
53. DiCarlo JB, Gupta EA, Solomon AR (2006) A pediatric case of nephrogenic fibrosing dermopathy: improvement after combination therapy. J Am Acad Dermatol 54:914-916
54. Auron A, Shao L, Warady BA (2006) Nephrogenic fibrosing dermopathy in children. Pediatr Nephrol 21:1307-1311